黑人种族是否会影响药物释放式支架时代的支架血栓的发展?
Sara D Collins1, Rebecca Torguson, Michael A Gaglia
1Department of Internal Medicine, Division of Cardiology, Washington Hospital Center, Washington, DC 20010, USA.
Circulation
|September 1, 2010
概括
黑人种族独立地预测药物释放支架植入后的支架血栓形成. 即使考虑到社会经济地位和并发性疾病,这种发现仍然存在,因此需要进一步研究潜在机制.
科学领域:
- 心脏病学 心脏病学
- 健康差异 在健康上的差异
- 医学研究 医学研究
背景情况:
- 以前的研究表明,黑人种族可能是药物释放支架 (DES) 植入后支架血栓形成 (ST) 的危险因素.
- 目前尚不清楚社会经济地位或并发症是否影响了这一关联.
研究的目的:
- 调查黑人种族是否是DES植入后确定的ST的独立预测因素.
- 确定社会经济地位或并发症是否会影响种族和性别之间的关系.
主要方法:
- 一项对比研究分析了1594名接受DES植入的黑人患者和5642名非黑人患者.
- 使用多变量考克斯回归分析,调整了相关疾病和家庭收入中位数.
- 克洛皮多格雷尔的合规性也被评估为潜在的混因素.
主要成果:
- 黑人患者年轻,患高血压,糖尿病,慢性功能衰竭和充血性心力衰竭的比例更高.
- 尽管黑人患者的克洛皮多格雷尔服药量较高,但多变量分析显示,黑人种族是确定的晚期ST的重要预测因素.
- 社会经济地位,以收入中位数表示,与ST无关.
结论:
- 黑人种族是确定的药物释放支架血栓瘤的独立预测因素.
- 黑人患者中更高的克洛皮多格雷尔遵守性和缺乏与社会经济地位的关联表明可能涉及其他机制.
- 需要进一步的研究,以阐明导致这种种族差异的生物学或其他因素ST.
相关概念视频
Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
